Analysts are expecting a trio of struggling financial technology stocks to gain at least 40% over the next year, according to recent price target estimates.
In this analysis, S&P Global Market Intelligence considered major financial technology stocks trading the most below or above mean analyst price targets as of Dec. 20. Only stocks covered by at least three analysts and a price above $5 per share as of Dec. 20 were included in this analysis.
Currently, analysts are expecting shares of Evolent Health, a healthcare technology systems provider, to grow 82.0% over the next year, the highest implied upside of all fintech included in the analysis. Evolent's shares have slipped over the past year, losing 17.9% as of Dec. 20, including a 23.9% decline in the fourth quarter through Dec. 20.
Meanwhile, Unisys Corp. and Diebold Nixdorf Inc. had the second- and third-highest implied upside at 64.6% and 42.7%, respectively, as of Dec. 20. Unisys' stock has dropped by almost half over the last year, while Diebold's stock has lost almost a third of its value.
On the other hand, Appian Corp. has overshot analyst price targets by 16.9% as of Dec. 20, thanks to a strong 127.3% return since the stock's IPO in May.
Inovalon Holdings Inc., a healthcare technology company, and Paychex Inc., a payroll service provider, had the second- and third-largest implied downside at 13.0% and 9.2%, respectively.